Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data of control or anti-PD-1 antibody tolerant LLC cells

ABSTRACT: Even after anti-PD-1 antibody is administrated to subcutaneous model mouse using LLC cells, there are a few cells which survive, and these tolerant cells are considered to be the source of later recurrence. We used microarray analysis to explore the mechanism behind the tolerance to anti-PD-1 antibody in LLC cells

ORGANISM(S): Mus musculus

PROVIDER: GSE297630 | GEO | 2026/04/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Single-cell RNA sequencing data of anti-PD-1 antibody tolerant LLC cells

Project description:Even after anti-PD-1 antibody is administrated to subcutaneous model mouse using LLC cells, there are a few cells which survive, and these tolerant cells are considered to be the source of later recurrence. We performed single-cell analysis to explore the mechanism behind the tolerance to anti-PD-1 antibody in LLC cells

2026-04-15 | GSE297632 | GEO

Expression data of control or anti-PD-1 antibody tolerant LLC cells

Project description:Expression data of control or anti-PD-1 antibody tolerant LLC cells

| PRJNA1265498 | ENA

Expression data of anti-PD-1 antibody tolerant KLN205 cells

Project description:Even after anti-PD-1 antibody is administrated to subcutaneous model mouse using KLN205 cells, there are a few cells which survive, and these tolerant cells are considered to be the source of later recurrence. We used microarray analysis to explore the mechanism behind the tolerance to anti-PD-1 antibody in KLN205 cells

2026-04-15 | GSE297631 | GEO

Single-cell RNA sequencing data of anti-PD-1 antibody tolerant LLC cells

Project description:Single-cell RNA sequencing data of anti-PD-1 antibody tolerant LLC cells

| PRJNA1265500 | ENA

Expression data of anti-PD-1 antibody tolerant KLN205 cells

Project description:Expression data of anti-PD-1 antibody tolerant KLN205 cells

| PRJNA1265497 | ENA

Gene expression profiling of mature dendritic cells from mice s. c. treated with GM-CSF-gene transduced LLC cells (LLC/SeV/GM) or control cells (LLC, LLC/SeV/GFP)

Project description:Irradiated granulocyte macrophage-colony stimulating factor (GM-CSF)-transduced autologous tumor cells induce substantial antitumor immunity through the maturation and migration of dendritic cells (DCs). However, little is known about the key molecules involved in GM-CSF-sensitized DCs (GM-DCs) in tumor draining lymph nodes (TDLNs). We initially confirmed that mice subcutaneously injected with poorly immunogenic syngeneic Lewis lung carcinoma (LLC) cells transduced with Sendai virus encoding GM-CSF (LLC/SeV/GM) significantly rejected the tumor growth. Using microarray expression profiling, we obtained a large number of gene expression data files from GM-DCs and control DCs in TDLNs, and subjected them to network-based cluster analysis and unexpectedly unraveled the expression levels of type I IFNs-related genes specifically expressed in plasmacytoid DCs (pDC) were robustly up-regulated in GM-DCs. In vivo depletion assay showed that pDC-depleted mice treated with subcutaneous LLC/SeV/GM cells abrogated the antitumor effects observed in control mice. Moreover combination use of imiquimod for TLR7 triggering on pDC with irradiated LLC/SeV/GM cells induced a significant therapeutic antitumor effect with marked induction of CD9+ pDC with antitumor phenotype, whereas other control mice groups had only minimal to-modest antitumor responses, implicating that this combined vaccine strategy using imiquimod could be promising for improvement of GM-CSF-induced antitumor immunity. Mouse GM-CSF induced gene expression in mature dendritic cells in tumor draining lymph nodes from C57/BL6N female mouse was measured at 2 days after s.c. tumor challenge with GM-CSF gene-transduced LLC cells (LLC/SeV/GM) or control cells (LLC, LLC/SeV/GFP).

2013-09-30 | E-GEOD-43169 | biostudies-arrayexpress

Murine cells: MSC+LLC-serum-exosome vs LLC-serum-exosome

Project description:Murine cells: MSC+LLC-serum-exosome vs LLC-serum-exosome

| PRJNA490558 | ENA

Transcription profiling of Mus musculus PBS vs IL-5 trerated LLC cells, and LLC vs B16 cells at baseline conditions

Project description:PBS and Il-5 (22 pM) treated LLC and B16 cells were harvested after 24 hours, for comparison between: 1) PBS and IL-5 trerated LLC cells, and 2) btween LLC and B16 cells at baseline conditions.

2010-12-13 | E-MEXP-2490 | biostudies-arrayexpress

In vivo CRISPR Screening Identifying Therapeutic Target to Sensitize Anti-PD-1 Immunotherapy in Non-small Cell Lung Cancer

Project description:Although immunotherapy has achieved great success in lung adenocarcinoma (LUAD), only a subset of patients exhibit a favorable response. Leveraging LUAD mono-immunotherapy RNA-sequencing data, we identified differentially expressed genes associated with immunotherapy efficacy by comparing immunotherapy-sensitive and immunotherapy-insensitive patients. These genes were utilized to construct a customized sgRNA library. Two in vivo CRISPR screening models including Lewis lung carcinoma (LLC) and KrasG12D/Trp53-/-(KP) models were developed to identify novel targets regulating immunotherapy efficacy. After transducing the customized sgRNA library, LLC/KP-Cas9 library cells were injected into mice divided into three groups: Rag1-/- C57BL/6 immunodeficient mice treated with IgG antibody, and wild type C57BL/6 immunocompetent mice treated with anti-PD-1 antibody or isotype IgG antibody. Tumors were harvested after 2-4 weeks of treatment, genomic DNA was isolated, and next-generation sequencing (NGS) was performed to analyze sgRNA distribution. By comparing the sgRNAs detected in wild-type C57BL/6 immunocompetent mice treated with anti-PD-1 antibody versus isotype IgG, potential targets that regulating immunotherapy efficacy were identified.

2025-07-09 | GSE301822 | GEO

Stop Mole LLC

Project description:Stop Mole LLC

| PRJNA1097484 | ENA